Board Of Directorsabout : board of directors
Members Of The Board
 Dr. Aladar A. Szalay, who formed Genelux Corporation in 2001, is internationally recognized as a leader in the monitoring of gene regulation and in whole cell and live organism imaging using light-emitting proteins or protein fusions. Based on his long-time research interest and recent discoveries, the company is utilizing live microorganisms to locate (diagnose) and eliminate (therapy) human tumor xenografts. In addition, to guide the research and development program of Genelux Corporation, Dr. Szalay currently holds a university professor position at the Rudolf Virchow Center of Experimental Biomedicine, School of Medicine, and also at the Biocenter at the University of Würzburg in Würzburg, Germany, where he directs a research program with graduate students and post-doctoral fellows on whole body imaging. He was recently appointed to a full professor position in the Department of Radiation Oncology at the Rebecca and John Moores Comprehensive Cancer Center, at the University of California, San Diego. His previous academic appointments were: professor of molecular genetics and microbiology and founding director of the Center for Molecular Biology and Gene Therapy at Loma Linda University School of Medicine in Loma Linda, California; Canadian Pacific Endowed Chair Professor of biotechnology and molecular genetics at the University of Alberta in Edmonton, Canada; associate research scientist of molecular genetics at the Boyce Thompson Institute and adjunct professor at Cornell University in Ithaca, New York; and Gosney fellow at the California Institute of Technology in Pasadena, California. He has published over 160 scientific papers and holds over 50 issued patents and patent applications. Dr. Szalay is the recipient of the Wilhelm Exner Award (Medal for Excellence in Science) from Austria and the Alexander von Humboldt Prize from Germany, among others. He has functioned as an advisor for numerous research foundations, served on the Board of Directors and the Scientific Advisory Board for several biomedical start-up companies and was invited to serve as a genetic engineering, gene transfer and therapy expert for several multi-national pharmaceutical and diagnostic equipment manufacturing companies in the US, Europe and Japan.
 Dr. Albert Röder joined Genelux Corporation in 2004 after retiring from Roche Applied Science as Head of Global R&D and Marketing Support. In February of that year, he was elected to the Board of Directors of Genelux Corporation. His distinguished 33-year career in the pharmaceutical and diagnostics industries included several operative and leadership positions in research and development, manufacturing, marketing, strategy and business development within international cross-functional teams. Before joining Roche, Dr. Röder worked for Boehringer Mannheim, where he rose to Head of Research in Enzymology, Proteinchemistry and Chemistry, then to Head of the Global Product Supply Unit of its Business Unit, Biochemicals. He holds a PhD in organic chemistry from the University of Tübingen in Germany.
 Dr. Thomas served as the company's first Chief Financial Officer before leaving the post in 2004. He has been a member of the Board of Directors since August 2002. He is currently Dean of the School of Business and Management at La Sierra University in Riverside, California, where he teaches finance, economics and entrepreneurship, a position he has occupied since July 1988. Dr. Thomas holds MBA degrees in finance and marketing, an MA in political economy and a PhD in economics and politics. He has received numerous awards honoring his success as a passionate teacher who motivates students to seek and achieve excellence, among them the Freedom Foundation's Leavey Award for Excellence in Private Enterprise Education (1998), the Zapara Award to Teaching Excellence (1996) and the Riverside Chambers of Commerce Hero Award for Community Leadership (1995).
 Dr. Ronald Roy A. Simus joined Genelux Corporation as the Company's first investor in 2002 when the Company was first attempting to build its initial scientific discoveries into a biomedical research and development company. Since this time, Dr. Simus has been involved with the growth and evolution of the Company, including participating in the Company's management, corporate strategy, fundraising and operations. Today, he serves as the Company's Interim Secretary, its Vice President of Investor Relations and Investments and is also a member of the Company's Board of Directors. Dr. Simus holds a DDS and an MS in orthodontics and dentofacial orthopedics from Loma Linda University.
 Dr. Dennis Fenton recently retired from Amgen Corporation after a 26 year career that began at the company's inception in 1982. Starting as a Research Scientist, he held positions of increasing responsibility, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and was Amgen's first Executive Vice President. Prior to his tenure at Amgen, Dr. Fenton worked for Pfizer Central research in New Product Development from 1977 until 1981. He holds 5 US patents in microbiology and has published over 50 papers and abstracts. Since his retirement from Amgen in 2008, he has been an independent consultant and a member of the boards of Amira, Kythera, CytomX, Xenoport, Genzyme, Rutgers University, the Keck Graduate Institute and the Biotechnology Institute. Dr. Fenton holds a PhD in Microbiology from Rutgers University.
 Catherine J. Mackey, Ph.D. is founder of MindPiece Partners, a management consulting firm, and the former Sr. Vice President of Worldwide Research and Development for Pfizer Inc. She has 28 years of experience in the life science industry. After receiving her Ph.D. degree in microbiology from Cornell University in 1983, Dr. Mackey spent the first part of her career in the agricultural biotechnology industry. She worked her way up from bench scientist to Vice President and head of Research and Development for DEKALB Genetics Corporation. During those years she led the team that won the race to genetically engineer corn – a breakthrough that transformed the seed industry. Dr. Mackey and her team went on to apply this technology to create several first-in-class seed products. She also spearheaded the application of DNA typing to commercial corn breeding – causing fundamental change in product development and blurring the lines between 'conventional' and 'biotech' R&D. She was member of DEKALB's executive team which sold the company to Monsanto in 1998 at a market capitalization of $3.8B. Recognizing the potential application of genetics and genomic science to medicine, Dr. Mackey then joined Pfizer in 1999 to lead Genomic and Proteomic Sciences for human health at Pfizer's R&D headquarters in Groton, Conn. Soon she was appointed Vice President and head of Strategic Alliances with responsibility for Pfizer's substantial external research portfolio. In 2001 she was appointed Sr. Vice President of Pfizer Global R&D and Director of Pfizer La Jolla – a position she held for nine years. Dr. Mackey built Pfizer La Jolla into a vibrant R&D center of nearly 1000 people focused on the discovery and development of innovative medicines. In addition to her general management responsibilities at Pfizer La Jolla, Dr. Mackey was responsible for the exploratory development pipeline that delivered three key oncology compounds now on the market or in Phase III testing: Sunitinib (Sutent), Crizotinib (Xalkori), and Axitinib. Dr. Mackey serves on numerous boards, consistent with her passion for healthcare and innovation. She serves on the board of directors of several for-profit corporations: YM Biosciences (AMEX:YMI), Althea Technologies, and Genelux Corporation, and well as several non-profit organizations including CONNECT, BIOCOM, Rady Children's Hospital, and Project Concern International.
Copyright © 2011 Genelux |
Disclaimer
|